These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 1699309)
21. Similarities between LAK cells derived from human thymocytes and peripheral blood lymphocytes: expression of the NKH-1 and CD3 antigens. Ramsdell FJ; Gray JD; Golub SH Cell Immunol; 1988 Jun; 114(1):209-21. PubMed ID: 2967111 [TBL] [Abstract][Full Text] [Related]
22. Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. Keever CA; Welte K; Small T; Levick J; Sullivan M; Hauch M; Evans RL; O'Reilly RJ Blood; 1987 Dec; 70(6):1893-903. PubMed ID: 3118990 [TBL] [Abstract][Full Text] [Related]
23. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319 [TBL] [Abstract][Full Text] [Related]
24. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798 [TBL] [Abstract][Full Text] [Related]
25. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457 [TBL] [Abstract][Full Text] [Related]
26. Human fetal liver-derived CD7+CD2lowCD3-CD56- clones that express CD3 gamma, delta, and epsilon and proliferate in response to interleukin-2 (IL-2), IL-3, IL-4, or IL-7: implications for the relationship between T and natural killer cells. Hori T; Phillips JH; Duncan B; Lanier LL; Spits H Blood; 1992 Sep; 80(5):1270-8. PubMed ID: 1381242 [TBL] [Abstract][Full Text] [Related]
27. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion. Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000 [TBL] [Abstract][Full Text] [Related]
28. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Mackinnon S; Hows JM; Goldman JM Blood; 1990 Nov; 76(10):2037-45. PubMed ID: 2242425 [TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursors. Ballas ZK; Rasmussen W Cell Immunol; 1991 May; 134(2):296-313. PubMed ID: 1827045 [TBL] [Abstract][Full Text] [Related]
30. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation. Zarcone D; Viale O; Cerruti G; Tenca C; Malorni W; Arancia G; Iosi F; Galandrini R; Velardi A; Moretta A Cell Immunol; 1992 Sep; 143(2):389-404. PubMed ID: 1380897 [TBL] [Abstract][Full Text] [Related]
31. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity. Condiotti R; Nagler A Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185 [TBL] [Abstract][Full Text] [Related]
32. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Verfaillie C; Kay N; Miller W; McGlave P Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114 [TBL] [Abstract][Full Text] [Related]
33. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. Zhu HG; Zollner TM; Klein-Franke A; Anderer FA J Cancer Res Clin Oncol; 1994; 120(7):383-8. PubMed ID: 7514604 [TBL] [Abstract][Full Text] [Related]
34. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923 [TBL] [Abstract][Full Text] [Related]
35. Human cytotoxic effector cells: definition and analysis of activity. Ortaldo JR Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345 [TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193 [TBL] [Abstract][Full Text] [Related]
37. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
38. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT. Keever CA; Klein J; Leong N; Copelan EA; Avalos BR; Kapoor N; Cunningham I; Tutschka PJ Bone Marrow Transplant; 1993 Sep; 12(3):289-95. PubMed ID: 8241989 [TBL] [Abstract][Full Text] [Related]
39. LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes. Ferrarini M; Ferrero E; Fortis C; Poggi A; Zocchi MR Br J Cancer; 1990 Nov; 62(5):754-7. PubMed ID: 1700922 [TBL] [Abstract][Full Text] [Related]
40. Immunomagnetic isolation of NK and LAK cells. Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]